Valeo Pharma (CSE: VPH- OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive with news the company has received a notice of a positive recommendation to the Quebec Ministry of Health in regards to potentially seeing public reimbursement of their low molecular weight heparin biosimilar Redesca. Saviuk talks about this milestone and also when they are expecting the Canadian launch of Redesca and Redesca HP.
Valeo Pharma’s Redesca receives positive review for public reimbursement in Quebec
